Trial Profile

Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ingenol mebutate (Primary) ; Diclofenac
Indications Actinic keratosis
Focus Therapeutic Use
Sponsors LEO Pharma

Most Recent Events

01 Jun 2021 Results evaluating distinct subgroup of patients with AK might respond better to treatment with ingenol mebutate (IngMeb) versus diclofenac sodium (DS) published in the Journal of Dermatological Treatment
14 Oct 2017 Primary endpoint (Complete clearance of all AKs) has been met as per the results published in the British Journal of Dermatology
14 Oct 2017 Results published in the British Journal of Dermatology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com